

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
14 October 2004 (14.10.2004)

PCT

(10) International Publication Number
WO 2004/087673 A3

(51) International Patent Classification⁷: **C07D 225/02**,
313/00, 405/06, 495/04, A61K 31/365, 31/435, C07C
13/02, A61P 35/00

(21) International Application Number:
PCT/US2004/009571

(22) International Filing Date: 26 March 2004 (26.03.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/458,827 28 March 2003 (28.03.2003) US
60/496,165 19 August 2003 (19.08.2003) US

(71) Applicant (for all designated States except US):
**SLOAN-KETTERING INSTITUTE FOR CAN-
CER RESEARCH** [US/US]; 1275 York Avenue, New
York, NY 10021 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **DANISHEFSKY**,

Samuel, J. [US/US]; 22 Brayton Street, Englewood, NJ
07631 (US). **GAUL, Christoph** [DE/CH]; Im finsteren
Boden 17, 4125 Riehen (CH). **NJARDARSON, Jón, T.**
[IS/US]; 312 E. 66th Street, Apt. 1C, New York, NY
10021 (US).



(74) Agent: **LAGNEAU, Nadège, M.**; Choate, Hall & Stewart,
Exchange Place, 53 State Street, Boston, MA 02109 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,
ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),

[Continued on next page]

(54) Title: **MIGRASTATIN ANALOGS AND USES THEREOF**



(57) Abstract: The present invention provides compounds having formula (I), and additionally provides methods for the synthesis thereof, compositions thereof, and methods for the use thereof in the treatment of various disorders including cancer, metastasis and disorders involving increased angiogenesis, wherein R_1 - R_6 , R_8 - R_9 , Q , Y_1 , Y_2 and n are as defined herein.



Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(88) Date of publication of the international search report:
4 November 2004

Date of publication of the amended claims and statement:
10 March 2005

Published:

- with international search report
- with amended claims and statement

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.


AMENDED CLAIMS

[received by the International Bureau on 22 November 2004 (22.11.04);
claim 1 amended, claims 71-78 new]


independently hydrogen, or an aliphatic, heteroaliphatic, alicyclic, heteroalicyclic, aryl or heteroaryl moiety;

Y_1 and Y_2 are independently hydrogen, an aliphatic, heteroaliphatic, alicyclic, heteroalicyclic, aryl or heteroaryl moiety; or $-WR^{Y1}$; wherein W is independently -O-, -S- or $-NR^{Y2}$ -, wherein each occurrence of R^{Y1} and R^{Y2} is independently hydrogen, or an aliphatic, heteroaliphatic, alicyclic, heteroalicyclic, aryl or heteroaryl moiety; or Y_1 and Y_2 together with the carbon atom to which they

are attached form a moiety having the structure:



with the proviso that the compound does not have one of the following structures:




2. The compound of claim 1, wherein:

R_1 and R_2 are each independently hydrogen or substituted or unsubstituted lower alkyl; or R_1 and R_2 , taken together with the carbon atoms to which they are attached, form an epoxide, an aziridine or a substituted or unsubstituted cyclopropyl moiety;


R_3 is hydrogen, or substituted or unsubstituted lower alkyl or aryl; a prodrug moiety or an oxygen protecting group;

70. The method of claim 69 wherein the undesired angiogenesis occurs in syphilis, Mycobacteria infections, Herpes simplex infections, Herpes zoster infections, protozoan infections, in toxoplasmosis or Bartonellosis.


71. The compound of claim 7 having one of the structure:



wherein Y_1 and Y_2 are independently hydrogen, an alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl moiety; or $-WR^{Y1}$; wherein W is independently -O-, -S- or $-NR^{Y2}$ -, wherein each occurrence of R^{Y1} and R^{Y2} is independently hydrogen, or an alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl moiety; or Y_1 and Y_2 together with the carbon atom to which they are




72. The compound of claim 8 having one of the structure:




wherein Y_1 and Y_2 are independently hydrogen, an alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl moiety; or $-WR^{Y1}$; wherein W is independently -O-, -S- or $-NR^{Y2}$ -, wherein each occurrence of R^{Y1} and R^{Y2} is independently hydrogen, or an alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl

or heteroaryl moiety; or Y_1 and Y_2 together with the carbon atom to which they are

attached form a moiety having the structure:




73. The compound of claim 71 having the structure:



wherein n is 3; and Y_1 and Y_2 are independently hydrogen, an alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl moiety.

74. The compound of claim 72 having the structure:




wherein Y_1 and Y_2 are independently hydrogen, an alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl moiety.

75. The compound of claim 73 or 74, wherein R_5 and R_6 are each methyl.

76. The compound of claim 73 or 74, wherein R_3 is lower alkyl.

77. The compound of claim 76, wherein R_3 is methyl.

78. The compound of claim 73 or 74, wherein R_4 is OH, OAc, NH_2 or halogen, or R_4 taken together with the carbon atom to which it is attached forms a moiety

having the structure:  .

STATEMENT UNDER ARTICLE 19

Applicant respectfully submits that no new matter is presented with the amendment set forth in the "Letter for PCT Article 19 Amendment of Claims" filed concurrently herewith. Specifically, claim 1 has been amended in order to more clearly set forth what is intended as Applicants' invention (*i.e.*, to exclude compound 15 disclosed in Scheme 18 page 145 of the specification). Applicant had acknowledged their own preliminary work in the application as originally filed (See paragraphs [0376] through [0380] on pages 144-145 of the specification), which preliminary work was published in *Tet. Lett.*, 2002, 43, 9039 (See paragraph [0630] on page 211 of the application, as filed). Naturally, Applicant did not intend to encompass compounds known in the art at the time the application was filed. Applicant has amended claim 1 to reflect this.

Newly added claims 71-78 find support in the specification and claims, as originally filed. Specifically, claims 71-74 find support on page 141 of the specification, as well as in original claims 7 and 8. Support for new claims 75-78 can be found, for example, in original claims 10-13.

Applicant respectfully requests entry and consideration of this amendment in processing the application.